Belite Bio, Inc Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 33 rows, 33 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-04-21: Reporting owner Scholl Hendrik Peter; Form 4; Security Stock Option (right to buy); Transaction J Other acquisition or disposition (describe transaction).
- 2026-03-31: Reporting owner Chen Wan-Shan; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-03-31: Reporting owner Chuang Hao-Yuan; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-03-31: Reporting owner MATA NATHAN L.; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
BLTE insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-04-21 | Scholl Hendrik Peter Officer (Chief Medical Officer) | 4 | Stock Option (right to buy) Derivative · Indirect · By Bioptima Ltd. | J Other acquisition or disposition (describe transaction) | +10,000 10,000 owned after | $77.40 exercise price | $165.23 | 2026-04-23 |
| 2026-03-31 | Chen Wan-Shan Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +13,796 13,796 owned after | $0.44 exercise price | $159.44 | 2026-04-02 |
| 2026-03-31 | Chuang Hao-Yuan Director, Officer (Chief Financial Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +144,868 289,736 owned after | $0.44 exercise price | $159.44 | 2026-04-02 |
| 2026-03-31 | MATA NATHAN L. Officer (Chief Scientific Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +144,868 267,934 owned after | $6.00 exercise price | $159.44 | 2026-04-02 |
| 2026-03-31 | Lin Yu-Hsin Director, Officer (Chief Executive Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +206,954 413,908 owned after | $0.44 exercise price | $159.44 | 2026-04-02 |
| 2026-03-18 holding as of filing | Scholl Hendrik Peter Officer (Chief Medical Officer) | 3 | Stock Option (right to buy) Derivative · Indirect · By Bioptima Ltd. | Holding | $48.68 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Scholl Hendrik Peter Officer (Chief Medical Officer) | 3 | Stock Option (right to buy) Derivative · Indirect · By Bioptima Ltd. | Holding | $54.88 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Scholl Hendrik Peter Officer (Chief Medical Officer) | 3 | Stock Option (right to buy) Derivative · Indirect · By Bioptima Ltd. | Holding | $158.36 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | MATA NATHAN L. Officer (Chief Scientific Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $6.00 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | MATA NATHAN L. Officer (Chief Scientific Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $14.45 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | MATA NATHAN L. Officer (Chief Scientific Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $48.46 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Chuang Hao-Yuan Director, Officer (Chief Financial Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $0.44 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Chuang Hao-Yuan Director, Officer (Chief Financial Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $6.00 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Chuang Hao-Yuan Director, Officer (Chief Financial Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $14.45 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Chuang Hao-Yuan Director, Officer (Chief Financial Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $48.46 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Chuang Hao-Yuan Director, Officer (Chief Financial Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $54.88 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Chuang Hao-Yuan Director, Officer (Chief Financial Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $77.40 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Chuang Hao-Yuan Director, Officer (Chief Financial Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $93.02 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Chuang Hao-Yuan Director, Officer (Chief Financial Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $158.36 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Longo John Michael Director | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $6.00 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Longo John Michael Director | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $58.88 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Lu Ita Director | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $14.45 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Lu Ita Director | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $58.88 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Biddle Gary Clark Director | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $6.00 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Biddle Gary Clark Director | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $58.88 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Lin Yu-Hsin Director, Officer (Chief Executive Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $0.44 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Lin Yu-Hsin Director, Officer (Chief Executive Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $6.00 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Lin Yu-Hsin Director, Officer (Chief Executive Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $14.45 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Lin Yu-Hsin Director, Officer (Chief Executive Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $48.46 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Lin Yu-Hsin Director, Officer (Chief Executive Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $54.88 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Lin Yu-Hsin Director, Officer (Chief Executive Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $77.40 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Lin Yu-Hsin Director, Officer (Chief Executive Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $93.02 exercise price | 2026-03-18 | ||
| 2026-03-18 holding as of filing | Lin Yu-Hsin Director, Officer (Chief Executive Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $158.36 exercise price | 2026-03-18 |